Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors
暂无分享,去创建一个
Ju Han Kim | Seung-Yong Jeong | K. Lee | J. Ku | Yeul-Hong Kim | S. Shin | Byung-Joo Min | W. Lee | Myung-Eui Seo | S. Shin
[1] H. Aburatani,et al. Genetic Testing Distinguishes Multiple Chondroid Chordomas with Neuraxial Bone Metastases from Multicentric Tumors , 2020, Case reports in genetics.
[2] Yun Sung Cho,et al. Korean Genome Project: 1094 Korean personal genomes with clinical information , 2020, Science Advances.
[3] Vinod Sharma,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2020, The New England journal of medicine.
[4] J. Desai,et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.
[5] Harpreet Wasan,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2019, The New England journal of medicine.
[6] S. Ramsey,et al. Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer. , 2019, JCO clinical cancer informatics.
[7] A. Mcmillan,et al. Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. , 2019, Journal of Clinical Oncology.
[8] Lincoln D. Stein,et al. The International Cancer Genome Consortium Data Portal , 2019, Nature Biotechnology.
[9] S. van Vooren,et al. Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. , 2019, The Journal of molecular diagnostics : JMD.
[10] J. Baselga,et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial , 2019, JAMA oncology.
[11] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[12] Shujiro Okuda,et al. Next generation sequencing‐based gene panel tests for the management of solid tumors , 2018, Cancer science.
[13] A. Ho,et al. Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A. Biankin,et al. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. , 2018, JCO precision oncology.
[15] Hyun Cheol Chung,et al. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients , 2018, Cancer research and treatment : official journal of Korean Cancer Association.
[16] Li Ding,et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.
[17] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[18] J. Mariadason,et al. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation , 2017, Molecular Cancer.
[19] R. Bjornson,et al. Korean Variant Archive (KOVA): a reference database of genetic variations in the Korean population , 2017, Scientific Reports.
[20] V. Miller,et al. Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study , 2017, JCO precision oncology.
[21] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[22] B. Taylor,et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[24] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[25] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.
[26] T. Kohno,et al. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials , 2016, Molecular Cancer.
[27] Daniel G. MacArthur,et al. The ExAC browser: displaying reference data information from over 60 000 exomes , 2016, bioRxiv.
[28] Zhihua Li,et al. Performance characteristics of the AmpliSeq Cancer Hotspot panel v2 in combination with the Ion Torrent Next Generation Sequencing Personal Genome Machine. , 2016, Regulatory toxicology and pharmacology : RTP.
[29] Birgit Funke,et al. VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data , 2015, Genetics in Medicine.
[30] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[31] Ling Lin,et al. MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis , 2015, Genes, chromosomes & cancer.
[32] D. Planchard,et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[34] C. Ki,et al. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes , 2015, Genetics in Medicine.
[35] S. Green,et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers. , 2015, Journal of medicinal chemistry.
[36] K. Flaherty,et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[38] P. Snijders,et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology , 2014, Cellular Oncology.
[39] K. Morikami,et al. The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor , 2014, Molecular Cancer Therapeutics.
[40] P. Goodfellow,et al. Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .
[41] R. Herbst,et al. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. , 2014 .
[42] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[43] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[44] Manash S. Chatterjee,et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.
[45] Yu-ping Wang,et al. Comparative Studies of Copy Number Variation Detection Methods for Next-Generation Sequencing Technologies , 2013, PloS one.
[46] Benjamin A. Logsdon,et al. Imputation of exome sequence variants into population- based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project. , 2012, American journal of human genetics.
[47] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[48] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.
[49] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[50] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[51] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[52] Yan Sun,et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. Grossman,et al. Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001) , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[54] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.